Vivian Rexroad, PharmD

CRS:

JHU

Role:

Pharmacy

Position:

Pharmacist, PharmD, Investigational Drug Pharmacy

Email:

vrexroa@jhmi.edu
  • Network Pharmacist, IMPAACT Leadership
  • Member, IMPAACT Multidisciplinary Protocol Review Group
  • Protocol team member for IMPAACT 1078, IMPAACT 1114,  IMPAACT 2000 and IMPAACT 2011
  • General Member (Pharmacist), Protocol Development and Implementation Subcommittee of the SMCCC (Mar 2016-Nov 2019)
  • Member, Pharmacy Working Group of the Protocol Development and Implementation Subcommittee (Mar 2016-Nov 2019)
  • Protocol team member, IMPAACT 2012
  • Protocol team member, IMPAACT 2013
  • Protocol team member, IMPAACT 2018
  • Protocol team member, IMPAACT 2021

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

P1108: A Phase I/II, Open-Label, Single Arm Study to...

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More